ENTYVIO Drug Profile

Summary for Tradename: ENTYVIO

High Confidence Patents:	4
Applicants:	1
BLAs:	2
Recent Clinical Trials:	See clinical trials for ENTYVIO

Recent Clinical Trials for ENTYVIO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Teva takeda	Phase 4
Benaroya Research Institute	Early Phase 1
University of California, San Diego	Early Phase 1

See all ENTYVIO clinical trials

Pharmacology for ENTYVIO

Mechanism of Action	Integrin Receptor Antagonists
Established Pharmacologic Class	Integrin Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENTYVIO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENTYVIO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,004,808		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,040,855		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,111,968		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	7,147,851		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ENTYVIO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,004,808	2036-07-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,040,855	2032-05-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,111,968	2036-08-10	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,143,752	2036-07-20	Patent claims search

ENTYVIO Market Analysis and Financial Projection

Last updated: February 16, 2026

Market Dynamics and Financial Trajectory for ENTYVIO (vedolizumab)

Overview

ENTYVIO (vedolizumab) is a monoclonal antibody developed by Takeda, approved by the US FDA in 2014 for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). It functions as an integrin receptor antagonist, blocking lymphocyte migration into the gastrointestinal tissue.

Market Size and Growth Potential

Current Market Valuation

• In 2022, the global inflammatory bowel disease (IBD) therapeutics market was valued at approximately $7.5 billion.
• ENTYVIO represented a substantial share, driven by its approval in UC and CD indications.

Projected Growth

• The IBD market is projected to reach $11.8 billion by 2030 (CAGR 5.8%), driven by increasing prevalence, expanding indications, and enhanced patient access.
• ENTYVIO's market share is expected to increase with the approval of biosimilars and new indications, including pediatric UC and Crohn’s disease.

Competitive Landscape

Key Competitors

Drug Name	Class	Indications	Launch Year	Key Market Share (2022)
Humira (adalimumab)	anti-TNF alpha	UC, CD, other autoimmune	2002	25%
Stelara (ustekinumab)	IL-12/23 inhibitor	UC, CD	2016	20%
Cimzia (certolizumab)	anti-TNF	CD	2008	10%
Entyvio	integrin receptor blocker	UC, CD	2014	15%

Market Dynamics

• Anti-TNF biologics dominate, but ENTYVIO competes through favorable safety profile and targeting a different pathway.
• The emergence of biosimilars for some competitors places pricing pressure on ENTYVIO.
• The clinical preference shifts as physicians consider safety, tolerability, and long-term efficacy.

Regulatory and Market Access

• ENTYVIO received EMA approval in 2015 and various additional indications since.
• The drug faces reimbursement challenges, notably in cost-sensitive markets.
• Payers increasingly evaluate biologics based on real-world data showcasing safety and cost-effectiveness.

Revenue Trajectory

Historical Revenue (2020-2022)

Year	Revenue (USD millions)	Growth Rate
2020	1,150	—
2021	1,375	19.6%
2022	1,560	13.4%

Forecasted Revenue

• Based on market expansion and increased prescribing, projected revenues could reach USD 2 billion by 2027.
• Growth depends on the uptake in emerging markets, expanded indications, and biosimilar competition.

Key Factors Influencing Future Performance

• Regulatory approvals for pediatric UC and CD could open new markets.
• Innovation in delivery or combination therapies may provide a competitive edge.
• Pipeline developments include potential new indications or improved formulations.

Risks and Challenges

• Biosimilar entry for other biologics may reduce pricing power.
• Clinical trial results for new indications or comparative efficacy could alter market share.
• Reimbursement policies and healthcare reforms influence access and sales.

Summary

ENTYVIO maintains a stable position in the IBD therapeutics market, with a growth trajectory influenced by expanding indications and geographic penetration. It faces increasing competition from biosimilars and alternative biologics, requiring strategic positioning through clinical evidence and market access.

Key Takeaways

• The global IBD market is projected to grow at around 6% CAGR through 2030.
• ENTYVIO’s revenue growth depends heavily on expanding indications and market penetration.
• Competition from anti-TNF agents and biosimilars challenges its market share.
• Regulatory approval for pediatric use could significantly expand its addressable population.
• Cost and reimbursement remain key factors in commercial success, especially outside North America and Europe.

Frequently Asked Questions

1. What are the primary indications for ENTYVIO?
Ulcerative colitis and Crohn’s disease in adults, with regulatory efforts underway to expand into pediatric populations.

2. How does ENTYVIO compare to anti-TNF biologics?
It has a different mechanism of action—integrin blockade—that may offer better safety or efficacy in certain patient subsets.

3. What is the impact of biosimilars on ENTYVIO’s market?
While biosimilars for some competitors threaten pricing and market share, ENTYVIO’s unique pathway may reduce direct biosimilar competition.

4. Are there any new regulatory approvals expected for ENTYVIO?
Yes, potential approvals for pediatric UC and CD are under review or in development.

5. What major market factors could influence ENTYVIO’s future sales?
Regulatory decisions, market access policies, competitive biosimilar entries, and clinical trial outcomes significantly impact sales.

---

References

1. MarketWatch. "Global Inflammatory Bowel Disease (IBD) Therapeutics Market." 2022.
2. Takeda Pharmaceuticals. "ENTYVIO (vedolizumab) prescribing information." 2022.
3. Evaluate Pharma. "Biologics Market Outlook 2023-2030."
4. FDA. "ENTYVIO Approval History."
5. IQVIA. "Global Pharmaceutical Market Data 2020-2022."